NEW REQUEST CYCLES MAB TREATMENTS

Beginning on Dec. 13, 2021, the state is switching the Monoclonal Antibodies Treatment Cycles to biweekly schedules.

What does this mean for you?

- Every 2 weeks, you will submit requests for direct shipments ONLY. Pick-up requests at Arrowhead Regional Medical Center will no longer be available unless it is for an urgent need.
- Adjust your inventory accordingly. The amount of mAb treatments you request should supply your facility for a minimum of 2 weeks. **We highly encourage you to request mAb treatments for up to 4 weeks if storage allows; to support walk-ins and possible winter surges.**

If you are interested in ordering monoclonal antibody treatments, please refer to [SB COVID-19 Monoclonal Antibody Treatment](#).

OMICRON VARIANT (B.1.1.529)

We are still learning about the new Omicron variant, how it spreads and infects individuals as well as how it responds to Monoclonal Antibody Treatments. Until we have more information on the Omicron strain, our efforts should continue to focus on combating the current variant(s) that are dominant in California and San Bernardino County, such as the Delta Variant. Please continue to use the treatments available, as you deem necessary, to treat your COVID-19 patients. We should remain vigilant of any new accredited research and data that may surface in the coming weeks.

EFFICACY OF BAMLANIVIMAB WITH ETESEVIMAB

There has been hesitation in ordering Bamlanivimab with Etesevimab as a monoclonal treatments due to claims of its efficacy. Available research states that both Casirivimab with Imdevimab (REGEN-COV) and Bamlanivimab used with Etesevimab (BAM/ETE) are effective treatments for COVID-19 and the Delta Variant. In early December, the Emergency Use Authorization (EUA) of Bamlanivimab used with Etesevimab was revised to be administered for all pediatric patients including newborns with mild to moderate
symptoms. The use of Bamlanivimab with Etesevimab together have retained activity against SARS-CoV-2 B.1.617.2 lineage (Delta).

For the full EUA revision written by the US Food and Drug Administration, please visit: Expansion of Monoclonal Treatment Emergency Use Authorization

THERAPEUTIC TREATMENT UPDATE

Additional methods for treatment of COVID-19 have become available. Furthermore, the U.S. Food and Drug Administration (FDA) is considering additional therapeutics for Emergency Use Authorization (EUA).

- On Nov. 30, the FDA advisory committee voted in favor of granting an EUA for the oral antiviral Merck’s Molnupiravir, preparing the way for an approval decision in the coming weeks.
  - Please note, this product is not authorized for use during pregnancy, please see the FDA briefing document for more information.
- On December 8, the FDA authorized an EUA for pre-exposure prophylaxis (PrEP) EVUSHELD (formerly AZD7442) by AstraZeneca.
- The California Department of Public Health (CDPH) is also expecting the oral antiviral Paxlovid, produced by Pfizer to become available in the future.

San Bernardino County is awaiting further information regarding the amount we will be allocated and which facilities are eligible to receive the therapeutics. You should have received an interest form on Friday, Dec. 10 to inquire if your facility is interested in these treatments. Please be advised that requests are not guaranteed. We will continue to update you as more information is released.

For more information please refer to the following resources regarding these various COVID-19 Therapeutic Treatments:

- Merck Molnupiravir News Release
- FDA Briefing Document Molnupiravir
- FDA: EUA authorization for Evusheld by AstraZeneca
- EUA EVUSHELD Dec. 8, 2021
- Pfizer Paxlovid